^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MCARH109

    i
    Other names: MCARH109, GPRC5D CAR cells, MCARH-109, MCARH 109
    Associations

    News

    Trials
    Company:
    BMS, Eureka Therap, Memorial Sloan-Kettering Cancer Center, Sanofi
    Drug class:
    GPRC5D-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    2ms
    MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma (clinicaltrials.gov)
    P1, N=17, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025
    Trial completion date • Trial primary completion date
    |
    SDC1 (Syndecan 1)
    |
    MCARH109
    4ms
    A Study of MCARH109 and MCARH125 in People With Multiple Myeloma (clinicaltrials.gov)
    P1, N=24, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    SDC1 (Syndecan 1)
    |
    MCARH109 • MCARH125
    1year
    Genetic Basis of Relapse after GPRC5D-Targeted CAR T Cells (ASH 2023)
    Our patients with heavily pretreated multiple myeloma may harbor greater tumor heterogeneity and genomic instability than previously described, which can facilitate clonal outgrowth of antigen-negative tumor cells under continuous selective pressure of GPRCRD-targeted CAR T cells. Potential strategies to mitigate antigen escape-mediated relapse in myeloma patients receiving T-cell engaging therapies including earlier use of these therapies, multi-antigen targeting, or combination approaches are being evaluated in ongoing trials.
    CAR T-Cell Therapy • IO biomarker
    |
    GPRC5D (G Protein-Coupled Receptor Class C Group 5 Member D)
    |
    GPRC5D expression
    |
    MCARH109
    2years
    Clinical Activity of BMS-986393 (CC-95266), a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)–Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study (ASH 2022)
    After screening and leukapheresis, pts received bridging therapy if needed, then lymphodepleting chemotherapy (fludarabine 30 mg/m2 + cyclophosphamide 300 mg/m2 daily for 3 days) followed by a single infusion of BMS-986393... At all tested dose levels, BMS-986393 demonstrated a favorable safety profile; both CRS and neurotoxicity were low-grade, and neurotoxicity was infrequent and short-lived. Dose escalation is ongoing; MTD has not been exceeded. Preliminary efficacy appeared promising; antitumor responses were observed, including pts with CR who were MRD-negative at month 3.
    Clinical • P1 data • IO biomarker
    |
    GPRC5D (G Protein-Coupled Receptor Class C Group 5 Member D)
    |
    cyclophosphamide • fludarabine IV • BMS-986393 • MCARH109
    over2years
    MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma (clinicaltrials.gov)
    P1, N=17, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2023 --> Aug 2024
    Trial completion date • Trial primary completion date
    |
    SDC1 (Syndecan 1)
    |
    MCARH109
    over2years
    A Study of MCARH109 and MCARH125 in People With Multiple Myeloma (clinicaltrials.gov)
    P1 | N=24 | Recruiting | Sponsor: Memorial Sloan Kettering Cancer Center
    CAR T-Cell Therapy • New P1 trial
    |
    MCARH109
    almost3years
    MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma (clinicaltrials.gov)
    P1, N=17, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=36 --> 17
    Enrollment closed • Enrollment change
    |
    SDC1 (Syndecan 1)
    |
    MCARH109
    over3years
    MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma (clinicaltrials.gov)
    P1, N=36, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Aug 2022 --> Aug 2023
    Trial completion date • Trial primary completion date
    |
    SDC1 (Syndecan 1)
    |
    MCARH109
    4years
    MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma (clinicaltrials.gov)
    P1, N=36, Recruiting, Memorial Sloan Kettering Cancer Center
    New P1 trial
    |
    SDC1 (Syndecan 1)
    |
    MCARH109